Patent Application
20090280176
Alprazolam is an antianxiety agent of the benzodiazepine class. The chemical name of alprazolam is 8-chloro-1-methyl-6-phenyl-4H-s-triazolo[4,3-alpha][1,4]benzodiazepine. Used primarily for short-term relief of mild to moderate anxiety and nervous tension, alprazolam is also effective in the treatment of activity depression or panic attacks.
Alprazolam is available as an immediate release oral tablet (e.g., XANAX®) as well as an extended release tablet (e.g., XANAX XR®). XANAX immediate release tablets contain 0.25 mg, 0.5 mg, 1 mg or 2 mg of alprazolam and are indicated for the management of anxiety disorder and for the treatment of panic disorder (with or without agoraphobia). XANAX XR extended release tablets contain 0.5 mg, 1 mg, 2 mg or 3 mg of alprazolam and are indicated for the treatment of panic disorder (with or without agoraphobia). XANAX XR is a hypromellose-based extended release tablet.
The immediate release product produces efficacious levels of drug in the systemic circulation, but has to be administered multiple times a day (e.g., up to three to four times daily) in order to maintain efficacy. The extended release tablet, dosed once daily, produces a sustained drug plasma concentration profile with a relative bioavailability of 100% as compared to the XANAX immediate release tablet. Although having 100% relative bioavailability, the XANAX XR product has two shortcomings in that 1) the duration of effect is reported by patients to be not long enough and thus the medication needs to be dosed twice daily in certain patient populations and 2) patients report that there is a lack of effectiveness of the product immediately upon administration.
Thus, there remains a need for an alprazolam formulation that would address the shortfalls of the current XANAX XR product. Additionally, there is a need for an alprazolam formulation that has the potential to better control the fluctuations in drug plasma concentration at steady state (i.e., the difference between the peak to trough values) by delivering the drug using a combination of release rates. Better control of the drug plasma concentration fluctuations can result in lower adverse events as compared to the currently available immediate release and extended release alprazolam drug therapies.
The current invention provides a controlled release formulation of alprazolam for a once a day oral administration that is effective immediately upon administration, as well as through a period of time of at least 24 hours after administration. This once a day formulation of alprazolam comprises at least one immediate release (IR) component, and at least one extended release (XR) component comprising a release controlling material. The IR component of the formulation is such that at least 90% of the active agent contained in it is released within 30 min of administration. The XR component of the novel formulation releases alprazolam in vivo in a sustained manner, and may be customized to fit a specific pre-determined release profile. In one embodiment, 80% of the total amount of alprazolam is released in 10 to 24 hours.
The current invention additionally provides dosage forms for once a day administration of the controlled release formulation, as well as the method of treatment of generalized anxiety disorder, panic disorder, and anxiety associated with other CNS disorders using this formulation.
For the purposes of this invention, the term “alprazolam” includes alprazolam or any pharmaceutically acceptable salt thereof, as well as any crystalline and non-crystalline form, and any polymorph(s).
An “immediate release formulation” refers to a formulation that releases greater than or equal to about 80% of the pharmaceutical agent in less than or equal to about 1 hour.
“Sustained release” or “extended release” or “controlled release” is defined herein as release of a pharmaceutical agent in a continuous manner over a prolonged period of time.
By “prolonged period of time” is meant a continuous period of time of greater than about 1 hour, preferably, greater than about 4 hours, more preferably, greater than about 8 hours, more preferably greater than about 12 hours, more preferably still, greater than about 16 hours up to more than about 24 hours.
As used herein, unless otherwise noted, “rate of release” or “release rate” of a drug refers to the quantity of drug released from a dosage form per unit time, e.g., milligrams of drug released per hour (mg/hr) or a percentage of the total drug dose released per hour. Drug release rates for dosage forms are typically measured in vitro, i.e., a quantity of drug released from the dosage form per unit time measured in a laboratory under appropriate conditions and in a suitable fluid. The time at which a specified percentage of the drug within a dosage form has been released from said dosage form is referred to as the “Tx” value, where “x” is the percent of drug that has been released.
The release rates referred to herein are determined by placing the dosage form to be tested in an appropriate dissolution media bath. Aliquots of the medium, collected at pre-set intervals, are then injected into a chromatographic system fitted with an appropriate detector to quantify the amounts of drug released during the testing intervals.
As used herein, unless otherwise noted, “delayed release” means there is no release of the pharmaceutical agent until a point in time where release begins.
“C” denotes the concentration of the drug in blood plasma, or serum, of a subject, and is generally expressed as mass per unit volume, for example nanograms per milliliter (ng/ml). For convenience, this concentration may be referred to herein as “drug plasma concentration,” “plasma drug concentration” or “plasma concentration” which is intended to be inclusive of a drug concentration measured in any appropriate body fluid or tissue. The plasma drug concentration at any time following drug administration is referenced as Ctime, as in C4hr or C9hr, etc.
The maximum plasma drug concentration during the dosing period is referenced as Cmax, while Cmin refers to the minimum plasma drug concentration during the dosing interval; and Cave refers to an average concentration during the dosing interval.
The “degree of fluctuation” for a dosing period is defined as a quotient (Cmax−Cmin)/Cave.
Persons skilled in the art will appreciate that plasma drug concentrations obtained in individual subjects will vary due to inter-patient variability in the many parameters affecting drug absorption, distribution, metabolism and excretion. For this reason, unless otherwise indicated, when a plasma drug concentration is listed, the value listed is the calculated mean value based on values obtained from a group of subjects tested.
The term “bioavailability” refers to an extent to which, and sometimes rate at which, the active moiety (drug or metabolite) enters the systemic circulation, thereby gaining access to the site of action.
“AUC” is the area under the plasma drug concentration-time curve and is considered to be the most reliable measure of bioavailability. The AUC is directly proportional to the total amount of unchanged drug that reaches the systemic circulation.
Side effect is defined herein as any secondary, usually adverse, effect of a drug.
The term “beads,” as used herein, includes, without any limitations on the nature and size thereof, any particles, spheres, beads, granules, pellets, particulates or any structural units that may be incorporated into an oral dosage form.
For the purposes of this application, two formulations are given in the “equivalent amount” if they produce an AUC within 80% to 125% of each other for the same period of time.
Throughout this application, “administered tid” means that ⅓ of the total daily dose of the active agent is being administered every 8 hours.
The current invention provides a controlled release formulation of alprazolam for once a day administration to a mammalian subject, which formulation releases alprazolam along a pre-determined release profile. In one embodiment, the profile is such that the blood concentration of the active agent at 24 hours after a single dose administration is not less than 75% of C24IR, wherein C24IR refers to the plasma concentration of drug obtained from the equivalent amount of alprazolam administered as an immediate release formulation TID.
Alternatively, the pre-determined release profile of the inventive formulation is such that a maximum steady state plasma concentration (Cmax) of alprazolam is not higher than the maximum plasma concentration produced by the equivalent amount of alprazolam administered as an immediate release formulation TID, and a minimum steady state plasma concentration (Cmin) which is not lower than 75% of the minimum plasma concentration produced by the equivalent amount of alprazolam administered as an immediate release formulation TID.
In another embodiment, the pre-determined release profile provides for a bioavailability, which is equivalent to that produced by the equivalent amount of alprazolam administered as an immediate release formulation TID.
In yet another embodiment, the profile is such that the degree of fluctuation is in the range of from 50% to 100% of the degree of fluctuation produced by the equivalent amount of alprazolam administered as an immediate release formulation TID.
Formulations of the current invention are characterized by a decreased level of undesirable side effects as compared to the equivalent amount of alprazolam administered as an immediate release formulation TID. The side effects that are potentially reduced include sedation, somnolence and lightheadedness, among others.
The inventive formulations of the present invention comprise alprazolam, which may be in a micronized form, and at least one release controlling material. Due to the presence of an extended release component, the formulation provides alprazolam release extended by at least two hours beyond the release duration of XANAX XR. The novel formulation additionally provides an early and fast rise of the plasma concentration of alprazolam to provide a relief to a patient soon after administration of the drug product due to the presence of an immediate release component. In some of the embodiments, the whole amount or a part of the active agent may be present in a micronized form to improve its solubility. Preferably, at least 50% of alprazolam is in the form of particles that are less than 10 microns in size. In the most preferred embodiment, at least 90% of alprazolam is in the form of the particles that are less than 10 microns in size.
In one embodiment, the once a day formulation of alprazolam comprises at least one IR component and at least one XR component comprising a release controlling material. The IR component of the formulation is such that at least 90% of the active agent contained in it is released within 30 minutes. Preferably, the IR component is such that at least 90% of the active agent is released within 15 minutes. The amount of the immediate release component in the formulation is from 0.5% to 35%; preferably, from 0.5% to 20%, of the entire formulation.
The release controlling material useful in the formulation of the present invention may be selected from ethylcellulose, polyvinyl acetate, poly(ethyl acrylate-co-methyl methacrylate-cotrimethylammonioethyl methacrylate chloride) (i.e. Eudragit® RS, Eudragit® RL), poly(ethyl acrylate-co-methyl methacrylate) (i.e. Eudragit® NE), cellulose acetate, cellulose acetate butyrate, cellulose acetate propionate, methylcellulose, waxes, and combinations thereof.
The formulations may additionally comprise a release delaying material, and optional pharmaceutically acceptable excipients, selected from wetting and solubility enhancing agents such as docusate sodium, sodium lauryl sulfate, polyethylene glycol, lecithin, poloxamer, the polysorbates, the polyoxyethylene ethers and the sorbitan esters: bulking agents such as microcrystalline cellulose, dicalcium phosphate, lactose, dextrose, mannitol, xylitol, sucrose, fructose, calcium sulfate, calcium carbonate, cellulose powder, maltodextrin, lactilol, maltilol, isomalt, talc and starch; binders such as povidone, starch, gelatin, maltodextrin, methylcellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, hydroxyethyl cellulose, methylcellulose, polyethylene oxide, carboxymethylcellulose, calcium phosphate, dicalcium phosphate, sucrose solution, dextrose solution, dextrin, acacia, alginic acid, tragacanth and locust bean gum; disintegrants such as crosslinked sodium carboxymethylcellulose, croscarmellose, sodium starch glycolate and crospovidone, microcrystalline cellulose, methylcellulose, potassium polacrilin, low substituted hydroxypropyl cellulose, starch, soy polysaccharides; glidants such as talc, starch and colloidal silicon dioxide and the metallic stearates; lubricants selected from talc, sodium stearyl fumarate, hydrogenated vegetable oils, glyceryl palmitostearate, glyceryl behenate, poloxamer, stearic acid, stearyl alcohol, cetyl alcohol, waxes, and the metallic stearates; and buffering agents and pH modulating agents such as aluminum hydroxide, ammonium bicarbonate, ammonium carbonate, ammonium phosphate, arginine, calcium acetate, calcium ascorbate, magnesium acetate, magnesium carbonate, potassium acetate, potassium bicarbonate, potassium carbonate, potassium phosphate dibasic, potassium sodium tartrate, potassium citrate, sodium citrate, sodium phosphate monobasic, sodium phosphate dibasic, sodium phosphate tribasic, sodium acetate, sodium bicarbonate, sodium ascorbate, sodium carbonate, fumaric acid, malic acid, tartaric acid, ascorbic acid, aspartic acid, alginic acid, glutamic acid, sorbic acid, and succinic acid.
The release delaying material used in the release delaying coating may also comprise an enteric polymer, which may be selected from the group consisting of poly(methyl acrylate-co-methyl methacrylate-co-methacrylic acid) (i.e. Eudragit® FS), cellulose acetate phthalate, cellulose acetate trimelliate, poly(methacrylic acid-co-methyl methacrylate) (i.e., Eudragit® L and Eudragit® S), hydroxypropyl methylcellulose acetate succinate, hydroxypropyl methylcellulose phthalate, polyvinyl acetate phthalate, shellac and zein.
The release delaying coating typically provides a release delay of from 0.5 to 4 hours, preferably from 1 to 3 hours.
In a further embodiment of the invention, the XR component alone, or both the XR component and the IR component, is contained in at least one population of beads comprising a carrier, a binder, and the active agent, wherein each population of beads is characterized by its own rate of release. The formulations of this embodiment may be produced by a variety of methods, well known in the art. For example, release controlling material may be coated onto the alprazolam containing beads, as shown in the non-limiting Example 3 below. The release controlling material coated beads of this embodiment may be prepared by first preparing the IR beads, and then coating them with the release controlling polymer. The IR beads are prepared by liquid or dry powder drug layering onto inert substrates (cores) (e.g. cellulose spheres, silicon dioxide, starch and sugar spheres), roller compaction granulation and wet granulation with extrusion and spheronization.
The drug layering process includes the preparation of a suspension of the alprazolam in a micronized or a non-micronized form along with a binder. The binder may be hypromellose (e.g., METHOCEL™ E5 Premium LV), hydroxypropyl cellulose, hydroxyethyl cellulose, povidone, dextrin, maltodextrin, acacia, guar gum, carboxymethylcellulose, gelatin, starch, sodium alginate, sucrose solution, dextrose solution, or combinations thereof Wetting agents may be additionally included in the formulation to assist with the dispersion of the drug in the aqueous medium. Wetting agents may include, but are not limited to, the ionic and nonionic surface active agents such as docusate sodium, sodium lauryl sulfate, polyethylene glycol, lecithin, poloxamer, the polysorbates, the polyoxyethylene ethers and the sorbitan esters. The drug suspension is applied to the core (e.g., cellulose spheres, silicon dioxide, starch or sugar spheres) in a fluid bed processor. The preferred core is sugar spheres.
The resultant drug layered bead can be overcoated with a film coating such as a hypromellose based coating (e.g., an Opadry film coating system) using a fluid bed processor to protect the bead from attrition of the drug layer during further processing, to minimize migration of the drug substance into the release controlling film during the application of the release controlling coating system and to prevent aggregation of the beads on storage.
The IR beads prepared as described above are used as substrates for the preparation of a number of populations of XR beads. The release controlling coating systems evaluated included ethylcellulose as aqueous dispersions (Surelease® Clear and Aquacoat® ECD) and in an organic solvent system, polyvinyl acetate (Kollicoat® SR 30D), Eudragit® RS 30D and Eudragit® RL 30D (poly(ethyl acrylate-co-methyl methacrylate-cotrimethylammonioethyl methacrylate chloride)) and Eudragit® NE 30 D (poly(ethyl acrylate-co-methyl methacrylate)). Additional release controlling polymers suitable for the preparation of extended release beads included cellulose acetate, cellulose acetate butyrate, cellulose acetate propionate, methylcellulose, and waxes (e.g., carnauba wax, microcrystalline wax).
To modulate the release profile of the release controlling polymer coated bead, a water soluble excipient may be added to the polymer coating system to serve as a pore former, thus increasing the permeability of the release controlling membrane. Hypromellose (METHCEL™ E5 Premium LV) is the pore former of choice for the ethylcellulose and polyvinyl acetate coating systems, whereas povidone (Kollidon K30) is the pore former of choice for the Eudragit® systems. The typical level of pore former used, expressed as a percentage of the total functional solids in the release controlling coating system, is on the range of 5% to 15%.
Other water soluble compounds can also serve as pore forming agents such as the polymers: gelatin, hydroxyethyl cellulose, hydroxypropyl cellulose, polyvinyl alcohol and Eudragit® E (poly(butyl methacrylate-co-(2-dimethylaminoethyl)methacrylate-comethyl methacrylate)), and the commercially available film coating systems such as Opadry or Opadry TI products, inorganic salts (e.g., sodium and potassium chloride), organic acids and salts of organic acids.
Alternatively, the formulations of the present invention may be produced by incorporating the release controlling material into the alprazolam containing beads thus forming the XR matrix beads, as shown in Example 5. The release controlling materials useful for this application may be selected from the group consisting of ethylcellulose, hydroxypropyl cellulose, hydroxyethyl cellulose, hydroxypropyl methylcellulose, methyl cellulose, carboxymethylcellulose, acrylic acid derivatives (e.g., carbomer homopolymer type A NF and carbomer homopolymer type B NF), polyethylene oxide, carrageenan, tragacanth, xanthan gum, alginic acid (and salts thereof), polyvinyl acetate, waxes, hydrogenated vegetable oils, methacrylic acid copolymer type A NF (Eudragit® L100), methacrylic acid copolymer type B NF (Eudragit® S 100), methacrylic acid copolymer type C NF (Eudragit® L100 55), ammonio methacrylate copolymer type A NF (Eudragit® RL 100), ammonio methacrylate copolymer type B NF (Eudragit® RS 100), poly(ethyl acrylate-co-methyl methacrylate) (i.e., Eudragit® NE and Eudragit® NM); poly(methyl acrylate-co-methyl methacrylate-co-methacrylic acid) (i.e., Eudragit® FS), poly(butyl methacrylate-co-(2-dimethylaminoethyl)methacrylate-comethyl methacrylate) (i.e., Eudragit® E), Compritol 888 ATO (glyceryl behenate), Precirol ATO 5 (glyceryl palmitostearate) and PEG glyceryl esters such as Gelucire 50/13. These compounds are used in the formulation in the amount of from 5% to 50%, preferably between 10% to 40% by weight of the XR component.
The XR matrix beads may be additionally coated with a layer of the release controlling material, which may be the same or different as the one incorporated into the XR matrix beads.
The specific amount of every bead population in the formulation is determined according to the pre-determined release profile and to the rate of release characteristic for every bead population. This rate of release is influenced by such factors as the amount of the active agent, nature and amount of the release controlling material and the amount of some excipients, such as pore formers in the case of release controlling coatings.
In another embodiment of the invention, the formulation is in the form of a multilayered tablet comprising at least one layer containing the IR component, and at least one layer containing the XR component. The XR containing layer may be presented as an IR layer coated with the release controlling material. Alternatively, the XR containing layer may comprise the active agent intermixed with the release controlling material. Such a multilayered tablet may comprise several IR containing layers and/or several XR containing layers, as well as an optional release delaying coating on some of the layers, thus opening the possibility for a variety of customized release profiles.
In yet another embodiment of the invention, a once a day formulation of alprazolam is an osmotic formulation, comprising at least one osmotic core, which is a single layer core or a multiple layer core. The drug may be incorporated into one or more layers of the multiple layer core. The IR component may be present as an overcoat (e.g., hypromellose based film coat) comprising the active agent.
The total amount of alprazolam in the formulation varies between 0.25 mg and 10 mg.
Any form of alprazolam, such as solvates (including hydrates), pharmaceutically acceptable salts, crystalline and non-crystalline forms, optical isomers and various polymorphs, may be used in the formulations of the current invention without any limitations. In one embodiment of the invention, the alprazolam used is a crystalline polymorph characterized by a powder X-ray diffraction pattern with at least peaks at diffraction angles 2.theta. of 9.56, 19.11, and 24.22. In another embodiment of the invention, another polymorphic form characterized by a powder X-ray diffraction pattern with at least peaks at diffraction angles 2.theta. of 13.14, 18.42, and 20.18 is used.
The formulations of the present invention may be presented in a dosage form selected from a tablet, a pill, a capsule, a caplet, a troche, a sachet, a cachet, a pouch, powder or sprinkles. In one embodiment, said dosage from is selected from a capsule, a compressed tablet, sprinkles or powder that contain the formulation of the present invention in the form of at least one population of beads.
In another embodiment, the dosage form may be a multilayered tablet wherein at least one IR component is in the form of an IR layer, and at least one XR component is in the form of an IR layer coated with the release controlling material. Another embodiment of the multilayered tablet can be a tablet-in-a-tablet comprising at least one XR layer surrounded by at least one IR layer.
The following examples are illustrative of the invention, but the invention is by no means limited to these specific examples. A person of ordinary skill in the art will find in these examples but one means to implement the instant invention. Further, while the instant examples have been presented in the context of rats for experimental convenience, the methods and reagents described herein can be readily translated to human application(s) by one of ordinary skill in the art from the teachings disclosed below.
Plasma concentration versus time curves for the alprazolam formulations containing extended release and immediate release bead populations were simulated using WinNonlin Version 5.0.1 based on pharmacokinetic data obtained from an in vivo study conducted in healthy subjects evaluating several alprazolam formulations and dissolution data for the separate bead populations. The dissolution data are shown in
for XR1, 4 h<=T60%<=6 h
for XR2, 11 h<=T60%<=14 h
for XR3, 5.5 h<T60%<=7 h
for XR4, 9 h<T60%<=11 h,
and at least one of the conditions selected from a following group was to be true:
1. at steady state in vivo,
for XR1, 1.10CmaxIR>=CmaxXR1>=0.80CmaxIR
for XR2, 0.90CmaxIR>=CmaxXR2>=0.60CmaxIR
for XR3, 1.10CmaxIR>=CmaxXR3>=0.80CmaxIR
for XR4, 0.90CmaxIR>=CmaxXR4>=0.60CmaxIR
2. at steady state in vivo,
Cmin XR1, XR2, XR3 and XR4 is at least 75% Cmin IR
3. for a single initial dose in-vivo,
for XR1, 8 h<=Tmax<=14 h
for XR2, Tmax>=16 h
for XR3, 10 h<=Tmax<=18
for XR4, Tmax>=16 h,
wherein CmaxIR and CminIR refer to the concentration of drug obtained from the equivalent amount of alprazolam administered as an immediate release formulation TID.
The results of the pharmacokinetic simulation for the seven exemplary formulations are summarized in Table 1 below. These formulations were selected as examples only, and in no way limit the range, compositions or properties of the formulations covered by the present invention.
The dissolution profiles of controlled release multi-bead formulations are presented in Table 2.
The extended release populations XR1-XR4 may be prepared starting from the IR beads by methods represented in the non-limiting Examples 2-4 below. Thus, the XR1 population is exemplified by beads B3 or B5 (Example 4); XR2 population is exemplified by beads B1, B2 or B7 (Example 3); XR3 population is exemplified by beads B4 or B6 (Example 4), and XR4 population is exemplified by beads B8 (Example 4).
A suspension of the micronized alprazolam and hypromellose (e.g., METHOCEL™ E5 Premium LV) binder was prepared. The drug suspension was applied to Sugar Spheres, NF cores in a fluid bed processor. The resultant drug containing beads were overcoated with a film of an Opadry film coating system using a fluid bed processor.
Examples of three immediate release bead formulations are provided in Table 3.
aThe drug layering dispersion and film coat formulations are prepared at a 20% overage in order to apply the target quantity per batch.
bRemoved during processing
A series of extended release bead formulations were developed. The IR beads of Example 2 served as a substrate for the extended release bead preparation. The IR beads were coated with release controlling coating systems such as Eudragit® NE 30 D (poly(ethyl acrylate-co-methyl methacrylate)).
To modulate the release profile of the extended release (XR) beads, a water soluble excipient was added to the polymer coating system to serve as a pore former thus increasing the permeability of the extended release membrane. Povidone (Kollidon K30) was the pore former of choice for the Eudragit® system.
Examples of two extended release (XR) bead formulations (B1 and B2) are provided in Table 4.
aThe extended release coating formulations is prepared at a 20% overage in order to apply the target quantity per batch.
bThe usage level of Eudragit ® NE 30 D is based on a solids assay value of 30.4% w/w.
cRemoved during processing
Extended release beads with the release delaying coating were produced by coating the extended release beads prepared by the process of Example 3 with Eudragit® FS 30 D (poly(methyl acrylate-co-methyl methacrylate-co-methacrylic acid)) as an enteric coating system.
Representative formulation of such beads, B4, is provided in Table 6 on the base of the B3 beads (Table 5).
aThe extended release coating formulations is prepared at a 20% overage in order to apply the target quantity per batch.
bThe usage level of Eudragit ® NE 30 D is based on a solids assay value of 30.4% w/w.
cRemoved during processing
aThe enteric coating formulation is prepared at a 20% overage in order to apply the target quantity per batch.
bThe usage level of Eudragit ® FS 30 D is based on a solids assay value of 30.3% w/w.
cRemoved during processing
Further examples of the extended release beads with the release delaying coating (B6 and B8) are presented in Table 8 on the base of the extended release beads (B5 and B7) (Table 7).
aThe extended release coating formulations is prepared at a 20% overage in order to apply the target quantity per batch.
bThe usage level of Eudragit ® NE 30 D is based on a solids assay value of 30% w/w.
cRemoved during processing
aThe enteric coating formulation is prepared at a 20% overage in order to apply the target quantity per batch.
bThe usage level of Eudragit ® FS 30 D is based on a solids assay value 30% w/w.
cRemoved during processing
The extended release matrix bead is manufactured by the process of roller compaction or extrusion/spheronization. An example matrix bead formulation for extrusion/spheronization is provided in Table 9.
A bilayer Extended Release/Immediate Release (XR/IR) tablet is manufactured by the process comprising the following steps:
Similarly, bulk excipients are first screened through a 40 mesh sieve. Polyethylene oxide, methacrylic acid copolymer Type A, maltodextrin and microcrystalline cellulose, are dry blended in a high shear granulator (Glatt-Powrex vertical granulator). The povidone is dispersed and dissolved in a sufficient quantity of a mixture of water and alcohol to granulate the mixture of the dry excipients. The micronized alprazolam is then added to the povidone solution and dispersed. The resulting dispersion is added to the dry excipients while granulating in the high shear granulator. The resulting granulation is dried in an oven or fluid bed dryer (Glatt GPCG-1) and then screened to obtain an optimal particle size distribution. The granules are then blended with the colloidal silicon dioxide, talc and magnesium stearate in a suitable blender (e.g. a twin shell—Patterson Kelly blender).
The Immediate Release and Extended Release granulations are simultaneously compressed into a bilayer tablet using a bilayer rotary tablet press (Kilian S250 ZS) and appropriate tooling.
While the invention has been described in connection with specific embodiments thereof, it will be understood that it is capable of further modifications and this application is intended to cover any variations, uses, or alterations of the invention following. In general, the principles of the invention and including such departures from the present disclosure as come within known or customary practice within the art to which the invention pertains and as may be applied to the essential features hereinbefore set forth and as follows in the scope of the appended claims.
This application claims priority from Provisional Application U.S. Application 61/051,522, filed May 8, 2008, incorporated herein by reference in its entirety.
| Number | Date | Country | |
|---|---|---|---|
| 61051522 | May 2008 | US |
